Docetaxel, bevacizumab, and gemcitabine for very high risk sarcomas in adolescents and young adults: A single‐center experience

    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.

Related Topics

    loading  Loading Related Articles